ASH 2022 | Outcomes of patients with CML with no molecular response within two years of TKI therapy

Aram Bidikian • 9 Jan 2023

ASH 2022

Aram Bidikian, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into a retrospective analysis which evaluated the outcomes of patients with chronic myeloid leukemia (CML) who did not achieve major molecular response (MMR) after treatment with tyrosine kinase inhibitors (TKIs). Results demonstrated that CML-related mortality was low among these patients, and Dr Bidikan explains that these findings should be considered in future guidelines for CML treatment. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.